{{Drugbox
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 414410253
| IUPAC_name = [Glu<sup>20</sup>,Ala<sup>21</sup>,Arg<sup>36</sup>,Ala<sup>38</sup>,His<sup>39</sup>,Pro<sup>40</sup>,Trp<sup>42</sup>]tissue factor pathway inhibitor (human)-(20-79)-peptide (modified on reactive bond region Kunitz inhibitor 1 domain containing fragment)<!--as reported in WHO Drug Information; not actual IUPAC name -->
<!-- Clinical data -->
| tradename = Kalbitor
| synonyms    = DX-88
| Drugs.com = {{drugs.com|monograph|ecallantide}}
| licence_US = ECALLANTIDE
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = C
| pregnancy_category = 
| legal_AU = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled -->
| legal_CA = <!-- Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_UK = <!-- GSL, P, POM, CD, or Class A, B, C -->
| legal_US = Rx-only
| routes_of_administration = [[Subcutaneous injection]]
<!-- Pharmacokinetic data -->
| elimination_half-life = 1.5–2.5 hours
| excretion = [[Renal]]
<!-- Identifiers -->
| IUPHAR_ligand = 6955
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 460738-38-9
| ATC_prefix = B06
| ATC_suffix = AC03
| PubChem = 118984459
| DrugBank = DB05311
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| UNII_Ref = {{fdacite|changed|FDA}}
| UNII = 5Q6TZN2HNM
| ChEMBL_Ref = {{ebicite|changed|EBI}}
| ChEMBL = 1201837
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 34983390
<!-- Chemical data -->
| C=305 | H=442 | N=88 | O=91 | S=8
| molecular_weight = 7053.83 g/mol
}}
'''Ecallantide''' (trade name '''Kalbitor''') is a [[pharmaceutical drug|drug]] used for the treatment of [[hereditary angioedema]] (HAE) and in the prevention of blood loss in [[cardiothoracic surgery]].<ref name=Lehmann>{{cite journal |author=Lehmann A |title=Ecallantide (DX-88), a plasma kallikrein inhibitor for the treatment of hereditary angioedema and the prevention of blood loss in on-pump cardiothoracic surgery |journal=Expert Opin Biol Ther |volume=8 |issue=8 |pages=1187–99 |date=August 2008 |pmid=18613770 |doi=10.1517/14712598.8.8.1187 |url=}}</ref> It is an inhibitor of the protein [[kallikrein]] and a 60-[[amino acid]] [[polypeptide]] which was developed from a [[Kunitz domain]] through [[phage display]] to [[Antibody mimetic|mimic antibodies]] inhibiting kallikrein.<ref name=Lehmann/>

==Medical uses==

===Angioedema===
On November 27, 2009, ecallantide was approved by the [[U.S. Food and Drug Administration|FDA]] for the treatment of acute attacks of hereditary angioedema for persons over 16 years of age.<ref name=Waknine>{{cite web |url=http://www.medscape.com/viewarticle/713401 |title=FDA Approves Ecallantide for Hereditary Angioedema |last=Waknine |first=Yael |publisher=[[Medscape]] |date=December 4, 2009 |accessdate=2009-12-07}}</ref>

For angioedema due to [[ACE inhibitors]] it does not appear to have a benefit.<ref>{{cite journal|last1=Lewis|first1=LM|last2=Graffeo|first2=C|last3=Crosley|first3=P|last4=Klausner|first4=HA|last5=Clark|first5=CL|last6=Frank|first6=A|last7=Miner|first7=J|last8=Iarrobino|first8=R|last9=Chyung|first9=Y|title=Ecallantide for the acute treatment of Angiotensin-converting enzyme inhibitor-induced angioedema: a multicenter, randomized, controlled trial.|journal=Annals of Emergency Medicine|date=February 2015|volume=65|issue=2|pages=204–13|pmid=25182544|doi=10.1016/j.annemergmed.2014.07.014}}</ref><ref>{{cite journal|last1=Scalese|first1=MJ|last2=Reinaker|first2=TS|title=Pharmacologic management of angioedema induced by angiotensin-converting enzyme inhibitors.|journal=American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists|date=15 June 2016|volume=73|issue=12|pages=873-9|doi=10.2146/ajhp150482|pmid=27261237}}</ref>

==Adverse effects==
The most common adverse effects are headache, [[nausea]], [[Fatigue (medical)|fatigue]] and [[diarrhea]]. Less common, but observed in more than 5% of patients in clinical trials, are [[respiratory tract infection]]s, fever, vomiting, itching and upper [[abdominal pain]]. Up to 4% of patients showed [[anaphylaxis]], which led to a [[black box warning]] in the US.<ref name="Dyax">{{cite web |author=Dyax Corp. |year=2009 |title=Full prescibing information Kalbitor |url=http://www.kalbitor.com/pdf/KalbitorFullPrescribingInformation.pdf |accessdate=2010-05-02}}</ref>

==Interactions==
{{as of|2011}}, no interaction studies have been conducted.<ref name="Dyax" />

==Mechanism of action==
HAE is caused by a [[mutation]] of the [[C1-inhibitor]] gene. Defective or missing C1-inhibitor permits activation of kallikrein, a [[protease]] that is responsible for liberating [[bradykinin]] from its precursor [[kininogen]].<ref>{{Cite journal 
| last1 = Bhoola | first1 = K. D. 
| last2 = Figueroa | first2 = C. D. 
| last3 = Worthy | first3 = K. 
| title = Bioregulation of kinins: Kallikreins, kininogens, and kininases 
| journal = Pharmacological reviews 
| volume = 44 
| issue = 1 
| pages = 1–80 
| year = 1992 
| pmid = 1313585
}}</ref><ref name="OffermannsRosenthal2008">{{cite book|author1=Stefan Offermanns|author2=Walter Rosenthal|title=Encyclopedia of Molecular Pharmacology|url=https://books.google.com/books?id=iwwo5gx8aX8C&pg=PA673|accessdate=11 December 2010|year=2008|publisher=Springer|isbn=978-3-540-38916-3|pages=673–}}</ref> An excess of bradykinin leads to fluid leakage from blood vessels, causing swelling of tissues typical of HAE.

Ecallantide suppresses this pathogenetic mechanism by selectively and reversibly inhibiting the activity of plasma kallikrein.<ref name="Dyax" />

==See also==
* [[Icatibant]], another drug for the treatment of HAE

==References==
{{reflist}}

{{B03, B05, B06}}

[[Category:Antibody mimetics]]
[[Category:Hydrolase inhibitors]]